查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1649519

全球抗纤溶药物市场预测（2025-2030）

Global Anti-Fibrinolytic Drug Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 144 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

抗纤溶药物市场预计将从 2025 年的 373.54 亿美元成长到 2030 年的 518.27 亿美元，复合年增长率为 6.77%。

抗纤维蛋白溶解药物旨在减缓血栓溶解，对于治疗月经过多和其他类型的出血至关重要。这些药物在防止鼻腔、口腔和女性生殖道等易发生纤维蛋白溶解的部位血栓破裂方面发挥重要作用。大多数手术都是在医院和诊所进行，因此对抗纤溶药物的需求尤其强烈。由于出血性疾病的增加、创伤和手术事故的增加、技术进步以及老年人口的增长等多种因素，全球抗纤溶药物市场预计将扩大。这些因素导致对抗纤溶药物的需求增加，以控制出血事件、控制创伤期间的失血以及提高治疗的有效性和安全性。老化社会特别容易受到出血性疾病及其併发症的影响，这进一步增加了对抗纤溶药物的需求。

全球抗纤溶药物市场的关键驱动因素

1. 外科手术中的外科手术：全球外科手术数量的增加是市场成长的主要驱动力。抗纤溶药物在各种外科手术中至关重要，包括心血管和牙科手术，因为它们可以减少出血。

2. 道路交通事故增加：世界卫生组织（WHO）估计，每年因道路交通事故死亡的人数约为135万人。由于这些药物具有防止溶栓和减少出血的作用，因此其需求受到道路交通事故发生率上升的影响很大。

3.月经失调管理：女性越来越多使用抗纤维蛋白溶解药物来控制月经量，有助于市场扩张。

4. 技术进步：药物配方和输送机制的创新提高了治疗效果和安全性。

地理见解

  • 北美：由于大型製药公司的存在和手术的高普及率，该地区预计将占据抗纤溶药物市场的大部分份额。
  • 亚太地区 (APAC)：由于道路交通死亡率和受伤率高，预计亚太地区将显着成长。该地区每年约有 645,000 人因道路交通事故丧生，对抗纤溶药物的需求强劲。此外，女性对月经健康的认识不断增强，进一步推动了市场的成长。

总而言之，由于手术需求、事故率上升、医疗技术的进步以及人口老化等人口因素，全球抗纤溶药物市场将大幅成长。

为什么要购买这份报告？

  • 深刻分析：获得深入的市场洞察，涵盖主要和新兴地区，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他子区隔。
  • 竞争格局：了解全球主要企业所采用的策略策略，并了解正确策略带来的潜在市场渗透率。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力做出策略决策，在动态环境中开闢新的业务流和收益。
  • 受众广泛：对于新兴企业、研究机构、顾问公司、中小企业和大型企业都有益且具有成本效益。

它有什么用途？

产业与市场分析、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

研究范围

  • 2022 年至 2030 年的实际资料和预测
  • 成长机会、挑战、供应链前景、法规结构、顾客行为、趋势分析
  • 竞争定位、策略与市场占有率分析
  • 各地区（包括细分市场和国家）的收益成长和预测分析
  • 公司概况（策略、产品、财务、主要发展等）

目录

第 1 章 简介

  • 市场概况
  • 市场定义
  • 研究范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 研究过程

第三章执行摘要

  • 主要发现
  • 分析师观点

第四章 市场动态

  • 市场驱动因素
  • 市场限制
  • 波特五力分析
  • 产业价值链分析

第 5 章。

  • 介绍
  • 外科手术
    • 心
    • 牙科
    • 其他的
  • 月经过多
  • 遗传性血管性水肿（HAE）

6. 全球抗纤溶药物市场（依给药途径划分）

  • 介绍
  • 口服
  • 注射

7. 全球抗纤溶药物市场（依最终用户划分）

  • 介绍
  • 医院和诊所
  • 门诊手术中心

8. 全球抗纤溶药物市场区域分布

  • 介绍
  • 北美洲
    • 按适应症
    • 依给药途径
    • 按最终用户
    • 按国家
  • 南美洲
    • 按适应症
    • 依给药途径
    • 按最终用户
    • 按国家
  • 欧洲
    • 按适应症
    • 依给药途径
    • 按最终用户
    • 按国家
  • 中东和非洲
    • 按适应症
    • 依给药途径
    • 按最终用户
    • 按国家
  • 亚太地区
    • 按适应症
    • 依给药途径
    • 按最终用户
    • 按国家

第九章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争仪錶板

第十章 公司简介

  • Pfizer Canada ULC
  • Zydus Pharmaceuticals, Inc.
  • Viatris Inc.
  • Xanodyne Pharmaceuticals, Inc.
  • American Regent, Inc.（Daiichi Sankyo Group）
  • Kedrion Biopharma
  • Bayer
  • Grifols
  • CSL Behring
简介目录
Product Code: KSI061613515

The global anti-fibrinolytic drug market is anticipated to grow at a CAGR of 6.77%, increasing from US$37.354 billion in 2025 to US$51.827 billion by 2030.

Antifibrinolytic drugs are designed to slow the dissolution of blood clots, making them essential for treating heavy menstrual bleeding and other types of hemorrhages. These agents play a critical role in preventing clot degradation in areas prone to fibrinolysis, such as the nasal cavity, oral cavity, and female reproductive tract. The demand for antifibrinolytic drugs is particularly strong in hospitals and clinics, where most surgeries occur. As the number of surgical procedures increases globally, the need for these medications to manage bleeding effectively is expected to drive market growth.The global antifibrinolytic drug market is anticipated to expand due to several factors, including a rise in bleeding disorders, an increase in trauma and surgical incidents, technological advancements, and a growing elderly population. These factors create a heightened demand for antifibrinolytic medications to manage bleeding episodes, control blood loss in trauma situations, and improve treatment efficacy and safety. The aging population is especially vulnerable to bleeding disorders and their complications, further increasing the need for these drugs.

Key Drivers of the Global Antifibrinolytic Drug Market:

1. Surge in Surgical Procedures: The increasing number of surgeries worldwide is a primary driver of market growth. Antifibrinolytic drugs are crucial during various surgical operations, including cardiovascular and dental procedures, as they help minimize bleeding.

2. Rise in Road Traffic Accidents: The World Health Organization (WHO) estimates that approximately 1.35 million fatalities occur annually due to road traffic accidents. Given that these drugs prevent clot lysis and mitigate blood loss, their demand is significantly influenced by the rising incidence of road injuries.

3. Management of Menorrhagia: The growing use of antifibrinolytic drugs among women to control heavy menstrual flow contributes to market expansion.

4. Technological Advancements: Innovations in drug formulations and delivery mechanisms enhance treatment effectiveness and safety.

Geographical Insights:

  • North America: This region is expected to hold a significant share of the antifibrinolytic drug market due to the presence of major pharmaceutical companies and a high prevalence of surgeries. The adoption of these drugs for managing menstrual flow also plays a key role in market growth.
  • Asia-Pacific (APAC): The APAC region is projected to experience substantial growth due to a high rate of road traffic injuries and accidents. With approximately 645,000 lives lost each year from road accidents in this region, there is a strong demand for antifibrinolytic medications. Additionally, increased health awareness among women regarding menstrual health further drives market growth.

In summary, the global antifibrinolytic drug market is poised for significant growth driven by surgical demands, rising accident rates, advancements in medical technology, and demographic factors such as an aging population.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Market Segmentation:

The global anti-fibrinolytic drug market is segmented and analyzed as below:

By Indication

  • Surgeries
  • Cardiac
  • Dental
  • Others
  • Menorrhagia
  • Hereditary Angioedema (HAE)

By Route of Administration

  • Oral
  • Injection

By End-User

  • Hospital and Clinics
  • Ambulatory Surgical Centers

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • UAE
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. GLOBAL ANTI-FIBRINOLYTIC DRUG MARKET BY INDICATION

  • 5.1. Introduction
  • 5.2. Surgeries
    • 5.2.1. Cardiac
    • 5.2.2. Dental
    • 5.2.3. Others
  • 5.3. Menorrhagia
  • 5.4. Hereditary Angioedema (HAE)

6. GLOBAL ANTI-FIBRINOLYTIC DRUG MARKET BY ROUTE OF ADMINISTRATION

  • 6.1. Introduction
  • 6.2. Oral
  • 6.3. Injection

7. GLOBAL ANTI-FIBRINOLYTIC DRUG MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospital and Clinics
  • 7.3. Ambulatory Surgical Centers

8. GLOBAL ANTI-FIBRINOLYTIC DRUG MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Indication
    • 8.2.2. By Route of Administration
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Indication
    • 8.3.2. By Route of Administration
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Indication
    • 8.4.2. By Route of Administration
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. Germany
      • 8.4.4.2. France
      • 8.4.4.3. UK
      • 8.4.4.4. Spain
      • 8.4.4.5. Italy
      • 8.4.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Indication
    • 8.5.2. By Route of Administration
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Israel
      • 8.5.4.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Indication
    • 8.6.2. By Route of Administration
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. Japan
      • 8.6.4.2. China
      • 8.6.4.3. India
      • 8.6.4.4. South Korea
      • 8.6.4.5. Indonesia
      • 8.6.4.6. Thailand
      • 8.6.4.7. Taiwan
      • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Pfizer Canada ULC
  • 10.2. Zydus Pharmaceuticals, Inc.
  • 10.3. Viatris Inc.
  • 10.4. Xanodyne Pharmaceuticals, Inc.
  • 10.5. American Regent, Inc. (Daiichi Sankyo Group)
  • 10.6. Kedrion Biopharma
  • 10.7. Bayer
  • 10.8. Grifols
  • 10.9. CSL Behring